Overview

A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

A multicenter randomized, single blind, active comparator controlled phase 2 study which is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin Injection (RD01) as maintenance therapy in the treatment of anemia in chronic renal failure patients with hemodialysis

Phase:

Phase 2

Details

Lead Sponsor:

Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Treatments:

Epoetin Alfa